GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EXMceuticals Inc (STU:9OM1) » Definitions » Net-Net Working Capital

EXMceuticals (STU:9OM1) Net-Net Working Capital : €-0.02 (As of Mar. 2021)


View and export this data going back to 2019. Start your Free Trial

What is EXMceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

EXMceuticals's Net-Net Working Capital for the quarter that ended in Mar. 2021 was €-0.02.

The industry rank for EXMceuticals's Net-Net Working Capital or its related term are showing as below:

STU:9OM1's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.53
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

EXMceuticals Net-Net Working Capital Historical Data

The historical data trend for EXMceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EXMceuticals Net-Net Working Capital Chart

EXMceuticals Annual Data
Trend Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.03 -0.13

EXMceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.13 -0.02 -0.02 -0.02

Competitive Comparison of EXMceuticals's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, EXMceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EXMceuticals's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EXMceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where EXMceuticals's Price-to-Net-Net-Working-Capital falls into.



EXMceuticals Net-Net Working Capital Calculation

EXMceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2020 is calculated as

Net-Net Working Capital(A: Jun. 2020 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.174+0.75 * 0.054+0.5 * 0-5.637
-0--0.307)/40.5205
=-0.13

EXMceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2021 is calculated as

Net-Net Working Capital(Q: Mar. 2021 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.229+0.75 * 0.175+0.5 * 0-1.932
-0-0)/75.7276
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


EXMceuticals  (STU:9OM1) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


EXMceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of EXMceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


EXMceuticals (STU:9OM1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
421 7th Avenue S.W., 30th Floor, Calgary, AB, CAN, T2P 4K9
EXMceuticals Inc is a bio-science company that believes in the potential health and wellness benefits of hemp and cannabis. EXM is an emerging player in the market, with ambition and potential to become the suppliers of highest-grade cannabis ingredients. It is creating an industrial-scale, GMP, Pharmaceutical Grade Extraction and Refining facility inside the European Union, near Lisbon Portugal. It has an existing and licensed cannabis R&D facility and pilot refinery in Lisbon Portugal. EXM is targeting the B2B marketplace and will supply pure ingredients and API's to the pharmaceutical, medicinal and wellness industry.

EXMceuticals (STU:9OM1) Headlines

No Headlines